Last reviewed · How we verify
Desloratadin
At a glance
| Generic name | Desloratadin |
|---|---|
| Sponsor | Max Zeller Soehne AG |
| Target | 5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Allergic urticaria
- Chronic idiopathic urticaria
- Common cold
- Nasal congestion
- Nasal discharge
- Seasonal allergic rhinitis
- Sneezing
- Vasomotor rhinitis
Common side effects
- Upper respiratory tract infections
- Diarrhea
- Fever
- Coughing
- Somnolence
- Bronchitis
- Otitis media
- Vomiting
- Urinary tract infection
- Varicella
- Appetite increased
- Emotional lability
Key clinical trials
- The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study (PHASE4)
- MOA Study of Ze 339 in Seasonal Allergic Rhinitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desloratadin CI brief — competitive landscape report
- Desloratadin updates RSS · CI watch RSS
- Max Zeller Soehne AG portfolio CI